Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers

doi:10.1001/jamadermatol.2018.5215

Comparative Study

. 2019 Apr 1;155(4):494-496.

doi: 10.1001/jamadermatol.2018.5215.

Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers

Joanie Pinard¹, Alisa N Femia², Michael Roman², Abeer Alsarheed¹, Cara Joyce³, Janice Lin^{1

4}, Ruth Ann Vleugels¹

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, New York University Ronald O. Perelman School of Medicine, New York.
³ Department of Public Health Sciences, Loyola University, Chicago, Illinois.
⁴ Division of Immunology & Rheumatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.

PMID: 30673076
PMCID: PMC6459090
DOI: 10.1001/jamadermatol.2018.5215

Comparative Study

Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers

Joanie Pinard et al. JAMA Dermatol. 2019.

. 2019 Apr 1;155(4):494-496.

doi: 10.1001/jamadermatol.2018.5215.

Authors

Joanie Pinard¹, Alisa N Femia², Michael Roman², Abeer Alsarheed¹, Cara Joyce³, Janice Lin^{1

4}, Ruth Ann Vleugels¹

Affiliations

¹ Department of Dermatology, Brigham and Women's Hospital and Harvard Medical School, Boston, Massachusetts.
² Department of Dermatology, New York University Ronald O. Perelman School of Medicine, New York.
³ Department of Public Health Sciences, Loyola University, Chicago, Illinois.
⁴ Division of Immunology & Rheumatology, Department of Medicine, Stanford University School of Medicine, Palo Alto, California.

PMID: 30673076
PMCID: PMC6459090
DOI: 10.1001/jamadermatol.2018.5215

Abstract

This study investigates the use of systemic treatment for clinically amyopathic dermatomyositis using natural language queries and ICD codes for amyopathic and hypomyopathic dermatomyositis.

PubMed Disclaimer

Conflict of interest statement

Conflict of Interest Disclosures: Dr Pinard reported serving as consultant/advisor for Celgene, Actelion, Janssen, Eli Lilly, and Novartis Canada. No other disclosures were reported.

Cited by

Higher Odds of Adverse Cutaneous Reactions in Patients With Dermatomyositis Treated With Hydroxychloroquine Compared With Methotrexate.
Allenzara A, Hollis A, Álvarez C, Lovelace H, Maczuga S, Helm M, Olsen N, Nelson A, Foulke G. Allenzara A, et al. ACR Open Rheumatol. 2023 Nov;5(11):594-599. doi: 10.1002/acr2.11605. Epub 2023 Sep 24. ACR Open Rheumatol. 2023. PMID: 37743678 Free PMC article.
Pitfalls in the Diagnosis and Management of an Unusual Presentation of Clinically Amyopathic Dermatomyositis: A Case Report Written With the Assistance of ChatGPT.
Jansz J, Tran HW, Sweiss NJ. Jansz J, et al. Cureus. 2023 Jul 14;15(7):e41879. doi: 10.7759/cureus.41879. eCollection 2023 Jul. Cureus. 2023. PMID: 37581145 Free PMC article.
Clinical pearls and promising therapies in myositis.
Connolly CM, Paik JJ. Connolly CM, et al. Expert Rev Clin Immunol. 2023 Jul-Dec;19(7):797-811. doi: 10.1080/1744666X.2023.2212162. Epub 2023 May 18. Expert Rev Clin Immunol. 2023. PMID: 37158055 Review.
Diagnosis and Management of Cutaneous Manifestations of Autoimmune Connective Tissue Diseases.
Goldman N, Han J, LaChance A. Goldman N, et al. Clin Cosmet Investig Dermatol. 2022 Oct 26;15:2285-2312. doi: 10.2147/CCID.S360801. eCollection 2022. Clin Cosmet Investig Dermatol. 2022. PMID: 36320926 Free PMC article. Review.
Exploring Dermatomyositis through an Interdisciplinary Lens: Pearls from Dermatology and Rheumatology.
Kassamali B, Mazori DR, LaChance AH, Christopher-Stine L. Kassamali B, et al. Int J Womens Dermatol. 2021 Sep 24;7(5Part A):576-582. doi: 10.1016/j.ijwd.2021.09.007. eCollection 2021 Dec. Int J Womens Dermatol. 2021. PMID: 35005177 Free PMC article. Review. No abstract available.

See all "Cited by" articles

References

1. Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26-30. doi:10.1001/archdermatol.2009.328 - DOI - PMC - PubMed
1. Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597-613. doi:10.1016/j.jaad.2005.10.041 - DOI - PubMed
1. Callander J, Robson Y, Ingram J, Piguet V. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. [published online May 11, 2016]. Br J Dermatol. 2018;179(6):1248-1255. doi:10.1111/bjd.14726 - DOI - PubMed
1. Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol. 2016;174(1):158-164. doi:10.1111/bjd.14227 - DOI - PubMed
1. Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002;138(9):1231-1233. doi:10.1001/archderm.138.9.1231 - DOI - PubMed

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions
Actions

Supplementary concepts

Actions

LinkOut - more resources

Full Text Sources
Medical
- Genetic Alliance

[1] Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26-30. doi:10.1001/archdermatol.2009.328 - DOI - PMC - PubMed

[2] Bendewald MJ, Wetter DA, Li X, Davis MD. Incidence of dermatomyositis and clinically amyopathic dermatomyositis: a population-based study in Olmsted County, Minnesota. Arch Dermatol. 2010;146(1):26-30. doi:10.1001/archdermatol.2009.328 - DOI - PMC - PubMed

[3] Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597-613. doi:10.1016/j.jaad.2005.10.041 - DOI - PubMed

[4] Gerami P, Schope JM, McDonald L, Walling HW, Sontheimer RD. A systematic review of adult-onset clinically amyopathic dermatomyositis (dermatomyositis siné myositis): a missing link within the spectrum of the idiopathic inflammatory myopathies. J Am Acad Dermatol. 2006;54(4):597-613. doi:10.1016/j.jaad.2005.10.041 - DOI - PubMed

[5] Callander J, Robson Y, Ingram J, Piguet V. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. [published online May 11, 2016]. Br J Dermatol. 2018;179(6):1248-1255. doi:10.1111/bjd.14726 - DOI - PubMed

[6] Callander J, Robson Y, Ingram J, Piguet V. Treatment of clinically amyopathic dermatomyositis in adults: a systematic review. [published online May 11, 2016]. Br J Dermatol. 2018;179(6):1248-1255. doi:10.1111/bjd.14726 - DOI - PubMed

[7] Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol. 2016;174(1):158-164. doi:10.1111/bjd.14227 - DOI - PubMed

[8] Galimberti F, Li Y, Fernandez AP. Clinically amyopathic dermatomyositis: clinical features, response to medications and malignancy-associated risk factors in a specific tertiary-care-centre cohort. Br J Dermatol. 2016;174(1):158-164. doi:10.1111/bjd.14227 - DOI - PubMed

[9] Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002;138(9):1231-1233. doi:10.1001/archderm.138.9.1231 - DOI - PubMed

[10] Pelle MT, Callen JP. Adverse cutaneous reactions to hydroxychloroquine are more common in patients with dermatomyositis than in patients with cutaneous lupus erythematosus. Arch Dermatol. 2002;138(9):1231-1233. doi:10.1001/archderm.138.9.1231 - DOI - PubMed

Save citation to file

Email citation

Add to Collections

Add to My Bibliography

Your saved search

Create a file for external citation management software

Your RSS Feed

Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers

Affiliations

Systemic Treatment for Clinically Amyopathic Dermatomyositis at 4 Tertiary Care Centers

Authors

Affiliations

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Supplementary concepts

LinkOut - more resources

Full Text Sources

Medical

Abstract

Conflict of interest statement

Similar articles

Cited by

References

Publication types

MeSH terms

Substances

Supplementary concepts

Related information

LinkOut - more resources

Full Text Sources

Medical